CCP stands for Covid-19 Convalescent Plasma, plasma collected from Covid-19 recovered patients. CCP contains antibodies that could neutralize SARS-CoV-2 and thus may improve disease course in patients with SARS-CoV-2.
SUPPORT-E Project: Severe acute respiratory syndrome virus 2 (SARS-CoV-2), responsible for COVID-19, has spread worldwide and has provoked a global health crisis.
To date, there are no direct viral medicinal products for the treatment of SARS-Cov-2. Only experimental drugs, associated to support care, are available as well as monoclonal antibodies, which are specifically used for the treatment of at risk patients such as those immunocompromised.
Hence, despite all, there is still a need for new curative strategies that preferably have already been used in clinical practice and that are widely available and scalable. Based on clinical experiences from previous epidemics, the use of convalescent plasma from recovered Covid-19 patients has been used producing still controversial results.
Therefore, successful adoption of this strategy in clinical practice in Europe still requires extensive clinical testing and would benefit from a coordinated approach between Blood Establishments (BEs), clinical centres and competent authorities across Europe to support and accelerate high-quality evaluation of CCP for the future.
In this context, the formulation of recommendations based on scientific and clinical insights coming from newly developed standardized assays and evaluation of CCP donor and recipient data will be of paramount importance.
Support High Quality
Support High Quality CCP Evaluation in clinical trials and monitored access use programmes
Deliver Recommendations for the collection and use of CCP in EU member states to treat Covid-19
Deliver Recommendations for future outbreaks
Ensure EU wide adoptions of recommendations and project legacy